CMS Forges Ahead with Price Transparency, Major Payment Reductions in Proposed OPPS Rule

Morgan Lewis

Morgan Lewis

The Centers for Medicare and Medicaid Services’ proposed outpatient prospective payment system rule contains a number of significant changes and proposals impacting hospital operations and payments in calendar year 2020, including a sweeping new price transparency program and consequential payment reductions for 340B drugs and evaluation and management services in grandfathered off-campus provider-based departments.

The Centers for Medicare and Medicaid Services (CMS) has proposed a rule regarding changes to the outpatient prospective payment system (OPPS) and ambulatory surgical center payment systems, among other changes, for calendar year (CY) 2020 (Proposed Rule). The Proposed Rule is filled with significant proposals impacting hospital operations and payments, and in some instances forges ahead without waiting for additional congressional or judicial direction. Perhaps most dramatic among the list of changes is the agency’s push toward a broad and inclusive pricing transparency program that may affect the negotiating of future managed care contracts. CMS also moves forward with major payment reductions for 340B drugs and evaluation and management (EM) services in grandfathered off-campus provider-based departments—both the subjects of pending litigation in US District Court of the District of Columbia.

The Proposed Rule is not without suggestions for greater flexibility, including permission for general rather than direct supervision for therapy in outpatient hospital settings. We provide a summary of several of the Proposed Rule’s key elements below. Hospitals should carefully evaluate the sweeping changes set forth in the proposal, and consider submitting comments to ensure their voices are heard as the agency contemplates turning these recommendations into rules. Comments are due September 27, 2019.

Price Transparency

For the last year, hospitals have been required to post on the internet a list of their standard charges under CMS rules. In frequently asked questions published in connection with last year’s final IPPS rule mandating such posting, CMS described the requirement as applying to “standard charges as reflected in its chargemaster.” The Proposed Rule offers a substantial widening of this obligation for hospitals.

On June 24, US President Donald Trump signed an executive order directing HHS to propose rules requiring hospitals to publish standard charge information on the internet, “including charges and information based on negotiated rates and for common or shoppable items and services.” The Proposed Rule intends to build on these actions by adopting a new Part 180 to 42 CFR requiring hospitals to make public “standard charge” data for a limited set of “shoppable services” in a “consumer-friendly” manner and form. These rates would be included in the list of standard charges for all items and services that hospitals are currently required to post online. In addition, hospitals would be required to publish the negotiated rates for 300 "shoppable" services (including 70 defined by CMS and 230 hospital-selected services) in a consumer-accessible and searchable manner.

Certain Definitions and Requirements

Standard Charges

CMS proposes to define “standard charges” to mean gross charges and payer-specific negotiated charges:

We believe the proposal to define standard charges as gross charges and payer-specific negotiated charges reflects the fact that a hospital’s standard charge for an item or service is not typically a single fixed amount, but, rather, depends on factors such as who is being charged for the item or service, and particular circumstances that apply to an identifiable group of people, including, for example, health care consumers that are insured members of third party insurance products and plans that have negotiated a rate on its members’ behalf.


The Proposed Rule defines a “gross charge” as the charge for an individual item or service that is reflected on a hospital’s chargemaster, absent any discounts (i.e., consistent with the previously published requirement), and adds to the definition “payer-specific negotiated charge” as the charge that the hospital has negotiated with a third-party payer for an item or service. The term “third party” would exclude self-paying patients. CMS knew that this substantial change to a hospital’s obligations for providing pricing information would raise concerns, and has invited feedback from the industry relating to the “unintended consequences” associated with posting “payer-specific negotiated charges.”


CMS is also seeking public comment on its proposal defining “hospital” for purposes of new Part 180 as follows:

[A]n institution in any State in which State or applicable local law provides for the licensing of hospitals, (1) is licensed as a hospital pursuant to such law or (2) is approved, by the agency of such State or locality responsible for licensing hospitals, as meeting the standards established for such licensing.


As such, the term “hospital” would include “each institution that satisfies this definition, regardless of whether that institution is enrolled in Medicare or, if enrolled, regardless of how Medicare designates the institution for its purposes,” according to CMS. Hospitals located in rural areas, critical access hospitals (CAHs), or hospitals that are not federally owned or operated but that treat special populations (such as children’s hospitals and state psychiatric hospitals) would fall within the proposed definition.

Exemptions would include federally owned or operated hospitals (e.g., Indian Health Service facilities, VA facilities, and military treatment facilities) because “these hospitals do not treat the general public, their rates are not subject to negotiation, and the cost sharing obligations for hospital provided services are known to their patients in advance.” Similarly, ambulatory surgery centers (ASCs) or “other non-hospital sites-of-care from which consumers may seek health care items and services” are also exempt.

Hospital Items and Services

Hospital “items and services” would be defined as all items and services provided by a hospital to a patient in connection with an inpatient admission or outpatient department visit for which the hospital has established a charge. Examples of “items and services” include supplies, procedures, room and board, use of the facility and other items (generally described as facilities fees), services of employed practitioners (generally described as professional charges), and any other items or services for which the hospital has established a charge, according to CMS.

Shoppable Service

A “shoppable service” would be defined as “a service package that can be scheduled by a health care consumer in advance.” CMS described the term further in the proposal:

Shoppable services are typically those that are routinely provided in non-urgent situations that do not require immediate action or attention to the patient, thus allowing patients to price shop and schedule a service at a time that is convenient for them.


The agency proposes that standard charges for shoppable services be displayed along with charges for “ancillary items and services” the hospital customarily provides as part of, or in addition to, the primary shoppable service. Such items may include laboratory, radiology, drugs, delivery room, and operating room (including postanesthesia and postoperative recovery rooms) fees; therapy services; hospital fees; room and board charges; charges for employed professional services; and other special items and services for which charges are customarily made in addition to a routine service charge.

Requirements for Making Standard Charge Data for Shoppable Services Public

The Proposed Rule details hospital requirements for making “consumer-friendly charge information” available to the public online. Such information must be displayed “in such a way that the payer-specific negotiated charge and associated data elements can be located and accessed easily by consumers.” To that end, the agency directs that hospitals “make public a list of payer-specific negotiated charges” for at least 300 shoppable services, including 230 hospital-selected shoppable services and 70 CMS-selected shoppable services. Hospitals would be required to include charges for services in conjunction with the primary service that is identified by a common billing code (e.g., Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), Diagnosis-Related Group (DRG)).

The 70 CMS-selected shoppable services are found in Table 37 of the Proposed Rule, categorized as follows: EM services, laboratory and pathology services, radiology services, and medicine and surgery services. Under CMS’s proposal, if a hospital does not provide one or more of the 70 CMS-selected shoppable services, it must select additional shoppable services such that the total number of shoppable services is at least 300. As for the 230 hospital-selected shoppable services, CMS proposes that hospitals select these services based on the utilization or billing rate of the services in the last year.

Hospitals would also be required to update the standard charge information at least annually with the date of the last update clearly indicated.

Monitoring and Enforcement of Price Transparency

CMS proposes to rely predominantly on complaints made to the agency by individuals or entities with respect to identifying instances of noncompliance and material violations of one of more requirements. Under the Proposed Rule, CMS would have the authority to impose a civil monetary penalty after giving warning notice to a noncompliant hospital, or subsequent to a request for a corrective action plan. If the hospital fails to respond to the agency’s request for a corrective action plan, or fails to comply with its requirements, CMS may impose a civil monetary penalty on the hospital not in excess of $300 per day, and publicize these penalties on its website. CMS also proposes to establish an appeals process for a hospital to request a hearing before an administrative law judge should it be subject to the new enforcement rules.

Altogether, the Proposed Rule represents a dramatic expansion of the agency’s prior interpretation of the statutory authority under Section 1001 of the Patient Protection and Affordable Care Act (Pub. L. 111-148), as amended by Section 10101 of the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152), that requires hospitals to make public their “standard charges.” It also reflects that “standard” can have two meanings, not just one, which, in our view, violates the plain meaning of the term “standard” and renders the entire proposal susceptible to challenge. CMS’s authority to levy civil monetary penalties is also questionable. Hospitals seeking to keep information that they reasonably deem confidential to remain that way will have a number of avenues to protect that information.

Operating Payment Update

For hospitals that successfully meet the hospital outpatient quality reporting requirements, CMS proposes to update the OPPS payment rates by 2.7% in CY 2020, reflecting a 1.45% increase over CY 2019. The FY 2020 update is based on the projected hospital market basket increase of 3.2% minus a productivity adjustment of 0.5 percentage points, according to CMS. The agency also proposes to update the CY 2020 ASC payment rate by 2.7%, a 0.6% increase over CY 2019.

Changes to Area Wage Index

CMS proposes to apply the fiscal year (FY) 2020 hospital Inpatient Prospective Payment System (IPPS) wage index to OPPS. Thus, any adjustments for the FY 2020 IPPS post-reclassified wage index for rural and urban areas would be reflected in the final CY 2020 OPPS wage index beginning January 1, 2020. CMS increased the wage index for IPPS hospitals with a wage index value (WIV) below the 25th percentile by half the difference between the otherwise applicable WIV for that hospital, and the 25th percentile WIV across all hospitals. This policy would begin in FY 2020 and be effective for at least four years. The urban to rural hospital reclassifications were also removed from the rural floor WIV calculation beginning in FY 2020. And to help mitigate any significant decreases in the WIVs of hospitals for FY 2020, CMS will impose a 5% cap on any decrease in a hospital’s wage index from its final wage index for FY 2019.

Site Neutrality Payment Reduction

Despite ongoing litigation challenging its statutory authority to do so, CMS proposes to move ahead with a two-year phase-in of the site-neutral payment rate finalized in CY 2019 for hospital outpatient clinic visits furnished in off-campus provider-based departments (PBDs), which were excepted from Congress’s mandate under the Bipartisan Budget Act of 2015 that new off-campus PBDs be paid on methodology other than OPPS. While Congress specifically excepted existing off-campus outpatient departments (OPDs) when it passed the law, CMS determined in last year’s OPPS rule that it would phase in a payment adjustment to these excepted OPDs that would equalize their reimbursement with nonexcepted PBDs for certain EM services. As a result, outpatient clinic visits would be paid at the physician fee schedule rate (i.e., 40% of the OPPS rate) in CY 2020. The proposed change would result in $810 million in reduced payments to hospitals under the Medicare program in 2020, and an average savings of $14 in cost sharing per clinic visit for beneficiaries, according to CMS.

The Proposed Rule for 2020 reflects the administration’s continued impatience with Congress relating to the agency’s desired site-neutrality policy for off-campus PBDs. The policy’s contrast with the law passed by Congress (which clearly delineated different treatment) provided hospitals with a solid legal basis to challenge last year’s final rule adopting phase one of the payment reduction in federal court. This year’s Proposed Rule suffers from the same legal frailties.

Drug Payment Policy

Medicare Part B reimbursement cuts for separately payable drugs and biologicals acquired under the 340B program would continue under the proposed OPPS rule. CMS proposes to pay an adjusted amount of the average sales price (ASP) minus 22.5% in CY 2020. Acknowledging the ongoing controversy and litigation with respect to the 340B payment adjustment, CMS has requested comment on alternative payment options for CY 2020 and potential remedies for CY 2018 and CY 2019 payments “in the event of an adverse ruling by the US Court of Appeals.” To that end, the agency is soliciting public comment “on the appropriate OPPS payment rate for 340B acquired drugs, including whether a rate of ASP+3 percent could be an appropriate remedial payment amount for these drugs, both for CY 2020 and for the purpose of determining the remedy for CYs 2018 and 2019.”

While the DC District Court ruled that CMS’s 2019 final rule regarding its “adjustment” to Part B payments for 340B drugs was unlawful, it did not enjoin the agency at the time of the decision. Instead, the court sought guidance from the parties on the appropriate remedy for the agency’s improper payment reductions. The Proposed Rule represents an opportunity for affected providers to comment on what may potentially serve as a resolution to the litigation, should CMS’s appeal to the circuit court be unsuccessful.

Quality Reporting Programs

To increase program alignment with respect to the Hospital Outpatient Quality Reporting (OQR) and Ambulatory Surgical Center Quality Reporting (ASCQR) programs, CMS is soliciting comments on utilizing a single set of patient safety measures for both programs.

Under the Hospital OQR Program, CMS proposes to remove one web-based measure for CY 2022 (External Beam Radiotherapy for Bone Metastases, OP-33). According to CMS, the costs and complexity associated with reporting the measure, which apparently imposed a substantial burden on hospitals, outweighs its continued use in the program. The agency is also soliciting public input on integrating four safety measures previously adopted for the ASCQR Program into the Hospital OQR Program in a future rulemaking: ASC 1-4 (including ASC-1: Patient Fall; ASC-2: Patient Burn; ASC-3: Wrong Site, Wrong Side, Wrong Procedure, Wrong Implant; and ASC-4: All-Cause Hospital Transfers/Admissions).

Finally, the agency proposes to adopt one claims-based measure, ASC-19: Facility-Level 7-Day Hospital Visits After General Surgery Procedures Performed at Ambulatory Surgical Centers (NQF #3357), beginning with the CY 2024 payment determination.

Inpatient-Only List Modifications

In the continued trend toward greater outpatient medical capacity, CMS proposes to remove total hip arthroplasty from the inpatient-only list, making it eligible to be paid by Medicare on an outpatient basis. This will likely promote competition from ASCs with hospitals on a procedure whose profitability may offset losses on other less profitable procedures.

ASC Covered Procedures List (CPL)

Likewise, the Proposed Rule would add total knee arthroplasty (TKA), knee mosiacplasty, and six coronary intervention procedures to the list of covered surgical procedures eligible for Medicare payment when furnished in an ASC. CMS is soliciting comments on providing safeguards for beneficiaries who should not receive the TKA procedure in an ASC setting. The agency is also soliciting comments on redesigning the CPL “to improve physician[s’] ability to determine the setting of care as appropriate for a given beneficiary situation.”

Prior Authorization Requirements

To ensure the medical necessity of services that are generally considered cosmetic, CMS proposes implementing a prior authorization requirement for blepharoplasty, botulinum toxin injections, panniculectomy, rhinoplasty, and vein ablation.

Device Pass-Through Payments

The Proposed Rule would establish an alternative pathway to qualifying for device pass-through payment status under OPPS. Specifically, transformative devices meeting the FDA’s breakthrough device designation that have received FDA marketing authorization will not be evaluated for “substantial clinical improvement” when determining device pass-through payment status. This is similar to a proposal made in the IPPS rule, where CMS solicited public comment on how to revise “substantial clinical improvement” criterion for the device pass-through payment.

Supervision of Outpatient Therapeutic Services

In a policy change from prior years, CMS proposes to lower the minimum required level of supervision from direct supervision to general supervision for hospital outpatient therapeutic services provided by all hospitals and CAHs.

Our experience indicates that Medicare providers will provide a similar quality of hospital outpatient therapeutic services, regardless of whether the minimum level of supervision required under the Medicare program is direct or general.


Noting that the enforcement instructions and legislative actions in place since 2010 “have created a two-tiered system of physician supervision requirements for hospital outpatient therapeutic services for providers in the Medicare program,” CMS says it “has come to believe” that the direct supervisions requirement “places an additional burden on providers.” Further, the agency maintains that it has not learned of “any data or information from CAHs and small rural hospitals indicating that the quality of outpatient therapeutic services has been affected by requiring only general supervision for these services.” CMS is seeking comment on whether specific types of services, “such as chemotherapy administration or radiation therapy,” should be accepted from this proposal. While this is a welcome development, hospitals should still concentrate on making sure they will have the requisite documentation supporting general supervision, as general supervision is still not the same as “no” supervision.

Children’s Hospitals Within Hospitals

Stating that it believes “there is no Medicare payment policy rationale” for prohibiting grandfathered children’s hospitals within hospitals (HwHs) from increasing their bed counts, CMS is proposing to allow a grandfathered children’s HwH to increase its number of beds without the loss of its grandfathered status. To that end, the agency is seeking public comment on whether this proposal “could create unintended or inadvertent consequences.”

Two Midnight Rule: Medical Review Policies

CMS proposes to establish a one-year exemption from site-of-service claim denials and certain medical review activities for procedures that are removed from the inpatient only (IPO) procedure list under OPPS in CY 2020 and subsequent years. Specifically, the agency proposes that such procedures would not be eligible for referral to recovery audit contractors (RACs) for noncompliance with the two-midnight rule within the first calendar year of their removal from the IPO list. During the one-year period, Beneficiary and Family-Centered Care Quality Improvement Organizations (BFCC-QIOs) may review such claims in order to educate practitioners and providers on compliance with the two-midnight rule, but claims identified as noncompliant would not be denied with respect to the site of service under Medicare Part A.

Laboratory Date of Service

CMS is seeking comment on potential revisions to the laboratory date-of-service (DOS) policy with respect to (1) determining when a molecular pathology test is a hospital service; (2) limiting the laboratory DOS exception to tests designated by CMS as an advanced diagnostic laboratory test (ADLT); and/or (3) excluding blood banks and blood centers from the laboratory DOS exception.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morgan Lewis | Attorney Advertising

Written by:

Morgan Lewis

Morgan Lewis on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.